PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk provides medical equipment, supplies, and distribution services in Indonesia.
Business. PT UBC Medical Indonesia Tbk (LABS.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through the sale of medical products and is headquartered in Indonesia. It is listed on the Indonesia Stock Exchange (IDX) under the ticker symbol LABS.JK. Specific details regarding operating segments or geographic revenue breakdowns are not provided.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PT UBC Medical Indonesia Tbk (LABS.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through the sale of medical products and is headquartered in Indonesia. It is listed on the Indonesia Stock Exchange (IDX) under the ticker symbol LABS.JK. Specific details regarding operating segments or geographic revenue breakdowns are not provided.
The company maintains a relatively strong capital structure, with a debt-to-equity ratio of 0.31, indicating a conservative leverage position. However, its liquidity position is assessed as medium, with a current ratio of 1.94, suggesting the company has sufficient short-term assets to cover its liabilities, but not with a large buffer. The company reported negative net cash, as operating cash flow was -9,276,646,290 IDR, while free cash flow was 3,238,761,210 IDR. This suggests that capital expenditures, which amounted to -3,180,165,240 IDR, were partially offset by positive free cash flow.
Profitability metrics are not explicitly provided, but the company's capital structure and liquidity position suggest a relatively stable financial foundation. The debt-to-equity ratio of 0.31 is below the industry median, indicating a lower reliance on debt financing compared to peers. The company's free cash flow generation, despite negative operating cash flow, suggests that it is managing its capital expenditures effectively.
The company's geographic exposure is concentrated in Indonesia, as it is a domestic player in the medical equipment and supplies market. There is no indication of significant international operations or revenue diversification. The company's revenue concentration in a single country may expose it to local economic and regulatory risks.
The company's growth trajectory is not explicitly outlined in the available data, but the negative operating cash flow and capital expenditures suggest that it may be investing in expansion or modernization. The free cash flow of 3,238,761,210 IDR indicates that the company is generating some cash from operations, which could support future growth initiatives.
The company's risk profile includes a medium liquidity risk, as it has a current ratio of 1.94, which is sufficient but not robust. The risk of dilution is assessed as low, with no immediate pressure for share issuance. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.31, which reduces the risk of financial distress.
Recent events and filings do not provide specific details on the company's strategic initiatives or financial performance beyond the disclosed financials. The company's 10-K or equivalent filings would provide more detailed insights into its operations and risk factors.
- The company maintains a conservative debt-to-equity ratio of 0.31, indicating a strong capital structure.
- Free cash flow of 3,238,761,210 IDR suggests the company is generating cash from operations despite negative operating cash flow.
- The company's liquidity position is assessed as medium, with a current ratio of 1.94.
- The company's operations are concentrated in Indonesia, which may expose it to local economic and regulatory risks.
- The risk of dilution is low, with no immediate pressure for share issuance.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- PT UBC Medical Indonesia Tbk Market data — financials · 2026-05-28